GlobeNewswire Inc | May 6, 2021 07:30AM EDT

May 06, 2021

BOSTON, May 06, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced that its co-founder, president, and CEO, Axel Bolte, MSc, MBA, will participate in a fireside chat at the BofA Securities 2021 Virtual Healthcare Conference on Thursday, May 13, at 11:45 a.m. ET.

The fireside chat will be webcast live and can be accessed from the Investor & News section of Inozymes website under Events. An archived replay of the webcast will be available for up to 90 days following the event.

About Inozyme PharmaInozyme Pharma (Nasdaq: INZY) is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton. Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are initially focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies.

Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com.

ContactsInvestors:Inozyme PharmaStefan Riley, Director of Investor RelationsStefan.riley@inozyme.com

Media:SmithSolveAlex Van Rees(973) 442-1555 ext. 111Alex.vanrees@smithsolve.com